Bhargav Patel, Mercer University College of Pharmacy
Ulcerative colitis is a chronic inflammatory disease of the large intestine characterized by symptoms that include abdominal pain and bloody diarrhea. Patients may present with this condition between 15-30 years of age with standard treatment depending on the extent of involvement, disease severity, and other factors.  Medications such as corticosteroids, tumor necrosis factor (TNF) antagonists, and aminosalicylates are proposed to assist with remission and maintenance medications may follow to prevent with a relapse.  Tofacitinib is an oral, small-molecule Janus kinase (JAK) inhibitor developed to treat rheumatoid arthritis and is also being investigated for the treatment of ulcerative colitis. Preferential inhibition of JAK1/JAK3 may cause interference in the JAK-STAT signaling pathway and prevent signaling to multiple immunological mediators such as Interleukin (IL)-2, IL-4, and interferon–γ.